NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024

Rhea-AI Summary

NewAmsterdam Pharma announced additional results from its Phase 3 BROOKLYN trial evaluating obicetrapib in patients with heterozygous familial hypercholesterolemia. The trial met its primary endpoint with LDL-C mean reduction of 36.3% at day 84 and 41.5% at day 365 versus placebo. Secondary endpoints showed significant improvements, including Lp(a) reduction of 45.9% at day 84 and 54.3% at day 365, and total LDL-P reduction of 52.5% at day 180. The drug demonstrated a favorable safety profile comparable to placebo, with a lower discontinuation rate (7.6%) compared to placebo (14.4%). The study involved 354 patients randomized 2:1 to receive 10 mg obicetrapib or placebo.

Positive

• Met primary endpoint with significant LDL-C reduction of 36.3% at day 84
• Achieved substantial Lp(a) reduction of 45.9% at day 84
• Demonstrated total LDL-P reduction of 52.5% at day 180
• Lower treatment discontinuation rate (7.6%) compared to placebo (14.4%)
• Safety profile comparable to placebo with no increase in blood pressure

Negative

• None.

Insights

Medical Research Analyst

The BROOKLYN Phase 3 trial results demonstrate exceptional efficacy for obicetrapib in treating HeFH patients. The 36.3% LDL-C reduction at day 84, sustained at 41.5% through day 365, represents significant clinical value. Most impressive is the 45.9% Lp(a) reduction, a important cardiovascular risk marker traditionally difficult to address.

The drug's multi-target impact on lipid profiles, including substantial reductions in total and small LDL particles (52.5% and 102.4% respectively), suggests potential superiority over existing treatments. The favorable safety profile, with lower discontinuation rates than placebo (7.6% vs 14.4%) and no concerning safety signals regarding diabetes or cardiovascular events, positions this as a potentially transformative therapy.

Financial Analyst

These robust clinical results significantly strengthen NewAmsterdam's market position. With a $2.28B market cap, successful commercialization could drive substantial value creation. The drug's oral administration and strong efficacy profile could capture significant market share from injectable PCSK9 inhibitors.

The data supports potential approval and commercial success, particularly given the large addressable market of HeFH patients inadequately controlled on current therapies. The upcoming TANDEM and BROADWAY study results in Q4 2024 could further catalyze stock movement. The comprehensive efficacy across multiple lipid parameters and clean safety profile suggests strong potential for broad market adoption and favorable pricing.

– Met primary endpoint with LDL-C mean reduction versus placebo of 36.3% at day 84 and 41.5% at day 365 –

– Lp(a) mean reduction versus placebo of 45.9% at day 84 and 54.3% at day 365 –

– Total LDL-P mean reduction versus placebo of 52.5% at day 180, with small LDL-P reduction of 102.4% –

– Safety results comparable to placebo –

NAARDEN, the Netherlands and MIAMI, Nov. 18, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced additional results from the Company’s Phase 3 BROOKLYN clinical trial (NCT05425745) evaluating obicetrapib in adult patients with heterozygous familial hypercholesterolemia (“HeFH”), whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy. The data were presented today in an oral late-breaker presentation at the American Heart Association (AHA) Scientific Sessions.

“We believe the additional data presented today underscore obicetrapib’s potential to significantly reduce not only LDL-C but also Lp(a), LDL particles, both total and small, along with several other biomarkers in HeFH patients when compared to treatment with placebo. Within the HeFH patient community, it is common for patients to be on multiple lipid-lowering therapies, and given the efficacy and safety profile observed to date, we believe obicetrapib has the potential, if approved, to provide physicians with a new tool to address unmet need in these patients,” said Stephen Nicholls, M.B.B.S., Ph.D., Director, Monash Victorian Heart Institute and Professor of Cardiology, Monash University.

“Despite the availability of lipid lowering therapies, CVD risk remains high and many people suffering from HeFH fail to meet their target cholesterol levels. We believe these additional results from the BROOKLYN pivotal trial further highlight obicetrapib’s potential to meaningfully reduce LDL-C, while also significantly improving additional CVD risk parameters including Lp(a), non- HDL-C, ApoB, and HDL-C,” said Michael Davidson, M.D., Chief Executive Officer of NewAmsterdam. “Together with the supportive data generated to date, these results reinforce our belief that, if approved, obicetrapib has the potential to meaningfully improve treatment for CVD patients worldwide. We look forward to building on these results with topline data from our TANDEM and BROADWAY studies expected in the fourth quarter of 2024.”

Phase 3 BROOKLYN Trial Results
The BROOKLYN trial met its primary endpoint, achieving an LS mean reduction of 36.3% (p < 0.0001) compared to placebo at day 84, which was sustained at day 365 with an LS mean LDL-C reduction of 41.5% (p < 0.0001). Secondary efficacy endpoints, including lipoprotein(a) (“Lp(a)”), which was 45.9% (p<0.0001) compared to placebo at day 84 and 54.3% (p=0.16) at day 365, apolipoprotein B (“ApoB”), high-density lipoprotein cholesterol (“HDL-C”) and non-HDL-C met statistical significance and results were consistent with data reported from NewAmsterdam’s prior clinical trials. The p-value for the LS mean for all secondary endpoints compared to placebo was <0.0001 following 84 days of treatment with obicetrapib.

	% LS mean change from baseline					Obicetrapib LS mean % change compared to placebo
	Placebo (n=118)			Obicetrapib (n=236)				p-value
LDL-C		0.3%		-36.1%		-36.3%		<0.0001
Lp(a)		10.5%		-35.4%		-45.9%		<0.0001
Non-HDL-C		2.8%		-31.6%		-34.5%		<0.0001
ApoB		2.9%		-21.5%		-24.4%		<0.0001
Total LDL particles		10.7%		-41.8%		-52.5%		<0.0001
Small LDL particles		32.4%		-70.0%		-102.4%		<0.0001
HDL-C		1.3%		140.0%		138.7%		<0.0001
Note: As of day 84, except for particle data as of day 180

“We are very encouraged by these additional results from BROOKLYN, where we observed obicetrapib’s lipid- and lipoprotein-lowering capabilities in a difficult to treat patient population that, despite being on multiple lipid-lowering therapies, still has elevated LDL-C,” said John Kastelein, M.D., Ph.D., FESC, Chief Scientific Officer of NewAmsterdam. “We are also pleased with the overall tolerability profile, including adverse events of special interest.”

Obicetrapib was observed to be well tolerated, with safety results comparable to placebo and no increase in blood pressure. The treatment discontinuation rate for the obicetrapib arm was 7.6% versus 14.4% for placebo. Adverse events of special interest are summarized in the table below.

​	Placebo N=118 n (%)	Obicetrapib 10 mg N=236 n (%)​
New diabetes or worsening glycemic control (%)	26 (22.0)	48 (20.5)
HbA1c increase >0.5% from baseline	6 (5.1)	8 (3.4)
Cardiovascular events	5 (4.2)	6 (2.6)

The data presentation is available through the publications and presentations section of the NewAmsterdam Pharma website at newamsterdampharma.com/publications.

Design of the Pivotal Phase 3 BROOKLYN Clinical Trial
The 52-week, global, pivotal, Phase 3, randomized, double-blind, placebo-controlled multicenter study evaluated the efficacy and safety of 10 mg obicetrapib compared to placebo as an adjunct to maximally tolerated lipid-lowering therapies in patients with HeFH whose LDL-C is not adequately controlled. The study was conducted at sites in North America, Europe and Africa. A total of 354 patients were randomized 2:1 to receive 10 mg obicetrapib or placebo dosed as a once-daily oral treatment, with or without food. The mean baseline LDL-C for enrolled patients in the obicetrapib arm was 123 mg/dL despite high intensity statin use reported by approximately 79% of patients during screening, with 54% on ezetimibe and 14% on PCSK9 inhibitors. Females comprised approximately 53% of the study population and the median age of participants at baseline was 57 years.

The primary endpoint was percent change from baseline in LDL-C of obicetrapib 10 mg compared to placebo after 84 days. Secondary endpoints also included percent changes from baseline of obicetrapib 10 mg compared to placebo after 84 days in HDL-C, non- HDL-C, ApoB, and Lp(a). The trial also evaluated the safety and tolerability profile of obicetrapib.

About NewAmsterdam’s Global Pivotal Phase 3 Program
NewAmsterdam’s global, pivotal Phase 3 clinical development program consists of four studies in over 12,250 patients, three for obicetrapib monotherapy and one for a fixed-dose combination (“FDC”) of obicetrapib and ezetimibe:

• BROOKLYN evaluated obicetrapib in patients with HeFH whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy. NewAmsterdam reported topline data from BROOKLYN in the third quarter of 2024.
• BROADWAY is evaluating obicetrapib in adult patients with established atherosclerotic cardiovascular disease (“ASCVD”) and/or HeFH whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy. NewAmsterdam completed enrollment of over 2,500 patients in July 2023 and expects to report topline data in the fourth quarter of 2024.
• TANDEM is evaluating obicetrapib as part of a FDC tablet with ezetimibe, a non-statin oral LDL-lowering therapy, in patients with established ASCVD or multiple risk factors for ASCVD and/or HeFH whose LDL-C is not adequately controlled despite being on maximally tolerated lipid-lowering therapy. NewAmsterdam completed enrollment of over 400 patients in July 2024 and expects to report topline data in the fourth quarter of 2024.
• PREVAIL is a cardiovascular outcomes trial evaluating obicetrapib in patients with a history of ASCVD whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy. NewAmsterdam completed enrollment of over 9,500 patients in April 2024.

About Obicetrapib
Obicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company’s Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company’s Phase 3 BROOKLYN trial, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company is conducting an additional Phase 3 pivotal trial BROADWAY, to evaluate obicetrapib as a monotherapy used as an adjunct to maximally tolerated lipid-lowering therapies to provide additional LDL-lowering for CVD patients, and TANDEM, to evaluate obicetrapib and ezetimibe as a fixed-dose combination. The Company began enrolling patients in BROADWAY in January 2022 and in TANDEM in March 2024; completing enrollment of BROADWAY in July 2023, and TANDEM in July 2024. The Company also commenced the Phase 3 PREVAIL cardiovascular outcomes trial in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of major adverse cardiovascular events, including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke and non-elective coronary revascularization. NewAmsterdam completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed dose combination with ezetimibe, for cardiovascular diseases have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company.

About NewAmsterdam
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.

Forward-Looking Statements
Certain statements included in this document that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the Company’s intellectual property and its ability to enforce, and sufficiency of, its patents, the Company’s business and strategic plans, the Company’s commercial opportunity, the therapeutic and curative potential of the Company’s product candidate, the Company’s clinical trials and the timing for enrolling patients, the timing and forums for announcing data, the achievement and timing of regulatory approvals, and plans for commercialization. These statements are based on various assumptions, whether or not identified in this document, and on the current expectations of the Company’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions. Many actual events and circumstances are beyond the control of the Company. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political, and legal conditions; risks related to the approval of the Company’s product candidate and the timing of expected regulatory and business milestones, including potential commercialization; ability to negotiate definitive contractual arrangements with potential customers; the impact of competitive product candidates; ability to obtain sufficient supply of materials; global economic and political conditions, including the Russia-Ukraine and Israel-Hamas conflict; the effects of competition on the Company’s future business; and those factors described in the Company’s public filings with the Securities Exchange Commission. Additional risks related to the Company’s business include, but are not limited to: uncertainty regarding outcomes of the Company’s ongoing clinical trials, particularly as they relate to regulatory review and potential approval for its product candidate; risks associated with the Company’s efforts to commercialize a product candidate; the Company’s ability to negotiate and enter into definitive agreements on favorable terms, if at all; the impact of competing product candidates on the Company’s business; intellectual property related claims; the Company’s ability to attract and retain qualified personnel; ability to continue to source the raw materials for its product candidate. If any of these risks materialize or the Company’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that the Company does not presently know or that the Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect the Company’s expectations, plans, or forecasts of future events and views as of the date of this document and are qualified in their entirety by reference to the cautionary statements herein. The Company anticipates that subsequent events and developments may cause the Company’s assessments to change. These forward-looking statements should not be relied upon as representing the Company’s assessment as of any date subsequent to the date of this communication. Accordingly, undue reliance should not be placed upon the forward-looking statements. Neither the Company nor any of its affiliates undertakes any obligation to update these forward-looking statements, except as may be required by law.

Company Contact
Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com

Media Contact
Spectrum Science on behalf of NewAmsterdam
Bryan Blatstein
P: 1-917-714-2609
bblatstein@spectrumscience.com

Investor Contact
Precision AQ on behalf of NewAmsterdam
Austin Murtagh
P: 1-212-698-8696
austin.murtagh@precisionaq.com

FAQ

What were the primary results of NAMS's Phase 3 BROOKLYN trial for obicetrapib?

The trial achieved a 36.3% LDL-C reduction at day 84 and 41.5% at day 365 compared to placebo, meeting its primary endpoint in patients with heterozygous familial hypercholesterolemia.

What was the safety profile of obicetrapib in the BROOKLYN trial?

Obicetrapib showed a safety profile comparable to placebo, with a lower discontinuation rate of 7.6% versus 14.4% for placebo, and no increase in blood pressure.

How many patients participated in NAMS's BROOKLYN Phase 3 trial?

The study included 354 patients who were randomized 2:1 to receive either 10 mg obicetrapib or placebo as a once-daily oral treatment.

What were the secondary endpoint results for obicetrapib in the BROOKLYN trial?

Secondary endpoints showed Lp(a) reduction of 45.9% at day 84, total LDL-P reduction of 52.5% at day 180, and improvements in HDL-C, non-HDL-C, and ApoB levels.